Skip to main content
メニュー
Revvity logo
Contact us
JP
Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • Improving the throughput of a neuroprotection assay using the opera phenix high content screening system
Case Study

Improving the throughput of a neuroprotection assay using the opera phenix high content screening system

Neuroprotection-Assay-512

This case study shows how a previously-described neuroprotection assay was easily and directly transferred to the Opera Phenix® high-content screening system, with a 4-fold decrease in acquisition time. In the assay, primary rat neurons are co-cultured on top of rat-derived astrocytes. To induce axon degeneration experimentally, NGF is withdrawn, leading to neuronal cell death, while astrocytes remain healthy. This can be captured by two readouts: the total axon area and the total number of nuclei. Neuroprotective drug candidates lead to an increase in the total axon area while keeping the number of nuclei (astrocytes) constant. Decreasing nuclei counts indicate a cytotoxic effect.

Download the case study to learn how:

  • Primary neuron morphology is analyzed in a straightforward approach using Harmony® software
  • Careful assay optimization can increase throughput, and minimize the data burden, without compromising assay performance

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Download Resource

Improving the throughput of a neuroprotection assay using the opera phenix high content screening system

Download Case Study
Revvity Logo

©2025 Revvity - All rights reserved

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.